Cencora, Inc. (NYSE:COR – Get Free Report) declared a quarterly dividend on Wednesday, August 5th. Investors of record on Friday, August 14th will be given a dividend of 0.60 per share on Monday, August 31st. This represents a c) dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th.
Cencora has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 15 consecutive years. Cencora has a payout ratio of 13.9% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Cencora to earn $19.81 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 12.1%.
Cencora Stock Performance
Shares of NYSE:COR traded up $11.40 during midday trading on Wednesday, hitting $317.68. The company had a trading volume of 2,291,352 shares, compared to its average volume of 1,536,487. Cencora has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a fifty day moving average of $290.71 and a two-hundred day moving average of $314.85. The company has a market cap of $61.81 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 1.71 and a beta of 0.57. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.
Cencora declared that its board has approved a stock repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.
About Cencora
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
See Also
- Five stocks we like better than Cencora
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
